Personalized pharmacotherapy for Type 2 diabetes mellitus

被引：9

作者：

Sathananthan, Airani ^{[1
]}

Vella, Adrian ^{[1
]}

机构：

[1] Mayo Clin, Div Endocrinol Diabet & Metab, Dept Med, Rochester, MN 55905 USA

来源：

PERSONALIZED MEDICINE | 2009年 / 6卷 / 04期

关键词：

OCT; 1; pharmacogenetics; sulfonylureas; TCF7L2; Type 2 diabetes mellitus; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; INSULIN-SECRETION; SECONDARY FAILURE; INCREASED RISK; TCF7L2; GENE; VARIANT; SULFONYLUREA; THERAPY; POLYMORPHISMS; PIOGLITAZONE;

D O I：

10.2217/PME.09.3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.

引用

页码：417 / 422

页数：6

共 50 条

[31] Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice
Venkatachalapathy, Poongothai
Padhilahouse, Sruthi
Sellappan, Mohan
Subramanian, Tharunika
Kurian, Shilia Jacob
Miraj, Sonal Sekhar
Rao, Mahadev
Raut, Ashwin Ashok
Kanwar, Rupinder Kaur
Singh, Jitendra
Khadanga, Sagar
Mondithoka, Sukumar
Munisamy, Murali
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 1441 - 1455
[32] Optimization of pharmacotherapy in patients with type 2 diabetes mellitus with myocardial infarction or with unstable angina in history
Ivanova, L. A.
DIABETES MELLITUS, 2006, 9 (04): : 9 - 12
[33] Type 2 diabetes mellitus and cardiovascular risk; what the pharmacotherapy can change through the epigenetics
Andreeva-Gateva, Pavlina A.
Mihaleva, Ivelina D.
Dimova, Ivanka I.
POSTGRADUATE MEDICINE, 2020, 132 (02) : 109 - 125
[34] Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon
Rasheed, Huda Abdulbaki
Al-Kuraishy, Hayder M.
Al-Gareeb, Ali, I
Hussien, Nawar Raad
Al-Nami, Marwa S.
JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH, 2019, 10 (04) : 163 - 168
[35] Genetically Guided Mediterranean Diet for the Personalized Nutritional Management of Type 2 Diabetes Mellitus
Gkouskou, Kalliopi
Lazou, Evgenia
Skoufas, Efstathios
Eliopoulos, Aristides G.
NUTRIENTS, 2021, 13 (02) : 1 - 14
[36] Personalized Decision Support in Type 2 Diabetes Mellitus: Current Evidence and Future Directions
Michael J. Wilkinson
Aviva G. Nathan
Elbert S. Huang
Current Diabetes Reports, 2013, 13 : 205 - 212
[37] Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Koullias, Emmanouil S.
Koskinas, John
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (05) : 965 - 971
[38] Targeting the Epigenetic Marks in Type 2 Diabetes Mellitus: Will Epigenetic Therapy Be a Valuable Adjunct to Pharmacotherapy?
Odimegwu, Chioma Laura
Uwaezuoke, Samuel Nkachukwu
Chikani, Ugo N.
Mbanefo, Ngozi Rita
Adiele, Ken Daberechi
Nwolisa, Charles Emeka
Eneh, Chizoma Ihuarula
Ndiokwelu, Chibuzo Obiora
Okpala, Somkenechi C.
Ogbuka, Francis N.
Odo, Kenneth E.
Ohuche, Ijeoma Onyinyechukwu
Obiora-Izuka, Chinelo Elizabeth
DIABETES METABOLIC SYNDROME AND OBESITY, 2024, 17 : 3557 - 3576
[39] Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus - A meta-analysis
Norris, SL
Zhang, XP
Avenell, A
Gregg, E
Schmid, CH
Kim, C
Lau, J
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (13) : 1395 - 1404
[40] Personalized Decision Support in Type 2 Diabetes Mellitus: Current Evidence and Future Directions
Wilkinson, Michael J.
Nathan, Aviva G.
Huang, Elbert S.
CURRENT DIABETES REPORTS, 2013, 13 (02) : 205 - 212

← 1 2 3 4 5 →